KR101963914B1 - 수용성 막 단백질 및 이의 제조 방법 및 이의 사용 방법 - Google Patents

수용성 막 단백질 및 이의 제조 방법 및 이의 사용 방법 Download PDF

Info

Publication number
KR101963914B1
KR101963914B1 KR1020137024789A KR20137024789A KR101963914B1 KR 101963914 B1 KR101963914 B1 KR 101963914B1 KR 1020137024789 A KR1020137024789 A KR 1020137024789A KR 20137024789 A KR20137024789 A KR 20137024789A KR 101963914 B1 KR101963914 B1 KR 101963914B1
Authority
KR
South Korea
Prior art keywords
delete delete
receptor
gpcr
water
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137024789A
Other languages
English (en)
Korean (ko)
Other versions
KR20140027117A (ko
Inventor
슈구왕 장
알렉산더 리치
캐롤리나 코린
로타 티. 테글러
Original Assignee
매사추세츠 인스티튜트 오브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 매사추세츠 인스티튜트 오브 테크놀로지 filed Critical 매사추세츠 인스티튜트 오브 테크놀로지
Publication of KR20140027117A publication Critical patent/KR20140027117A/ko
Application granted granted Critical
Publication of KR101963914B1 publication Critical patent/KR101963914B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
KR1020137024789A 2011-02-23 2012-02-23 수용성 막 단백질 및 이의 제조 방법 및 이의 사용 방법 Active KR101963914B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161445740P 2011-02-23 2011-02-23
US61/445,740 2011-02-23
PCT/US2012/026353 WO2012116203A1 (en) 2011-02-23 2012-02-23 Water soluble membrane proteins and methods for the preparation and use thereof

Publications (2)

Publication Number Publication Date
KR20140027117A KR20140027117A (ko) 2014-03-06
KR101963914B1 true KR101963914B1 (ko) 2019-03-29

Family

ID=46721234

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137024789A Active KR101963914B1 (ko) 2011-02-23 2012-02-23 수용성 막 단백질 및 이의 제조 방법 및 이의 사용 방법

Country Status (14)

Country Link
US (4) US8637452B2 (https=)
EP (1) EP2709647B1 (https=)
JP (1) JP6263773B2 (https=)
KR (1) KR101963914B1 (https=)
CN (2) CN108752461A (https=)
AU (3) AU2012220558A1 (https=)
BR (1) BR112013020969A2 (https=)
CA (1) CA2827187C (https=)
CL (1) CL2013002419A1 (https=)
EA (1) EA201391041A1 (https=)
IL (2) IL227886A0 (https=)
MX (1) MX347038B (https=)
SG (2) SG10201701547VA (https=)
WO (1) WO2012116203A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201701547VA (en) 2011-02-23 2017-03-30 Massachusetts Inst Technology Water soluble membrane proteins and methods for the preparation and use thereof
EP2968135A4 (en) 2013-03-14 2016-10-26 Massachusetts Inst Technology INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES
WO2014176544A1 (en) * 2013-04-25 2014-10-30 The Trustees Of The University Of Pennsylvania Water soluble g-protein coupled receptor
WO2014176524A2 (en) 2013-04-25 2014-10-30 The Trustees Of The University Of Pennsylvania Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor
WO2015148820A1 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
GB2527286A (en) * 2014-06-11 2015-12-23 Rsr Ltd Glycoprotein hormone receptor mutations
US10961286B2 (en) 2014-08-15 2021-03-30 Cornell University Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
CN104198689A (zh) * 2014-08-25 2014-12-10 李洁 一种检测g-蛋白耦联受体对缩血管物质反应的方法
JP7061461B2 (ja) * 2015-02-18 2022-04-28 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜貫通タンパク質ならびにその調製および使用方法
CN104946674B (zh) * 2015-06-17 2018-05-01 山东大学 一种腺苷三磷酸/双磷酸酶及其编码基因与应用
CN106749602A (zh) * 2016-12-30 2017-05-31 武汉金开瑞生物工程有限公司 一种助表达序列及其在无细胞表达adcy2蛋白中的应用
WO2019046699A1 (en) * 2017-09-01 2019-03-07 Massachustetts Institute Of Technology NON-DETERGENT GPCR BIOELECTRONIC INTERFACES COUPLED TO THE 2D S-PROTEIN NETWORK, DEVICES AND METHODS OF USE THEREOF
JP7250283B2 (ja) * 2017-12-11 2023-04-03 アステラス製薬株式会社 細胞膜透過性ペプチド
CN108245686B (zh) * 2018-01-15 2019-08-13 中国科学院昆明动物研究所 人grk5基因的用途
WO2021195177A1 (en) * 2020-03-25 2021-09-30 Massachusetts Institute Of Technology Qty fc fusion water soluble receptor proteins
WO2021202186A2 (en) 2020-03-31 2021-10-07 Massachusetts Institute Of Technology Qty fc fusion receptor proteins
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089899A2 (en) * 2006-02-01 2007-08-09 Oklahoma Medical Research Foundation Water-soluble (g protein)-coupled receptor protein

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US544021A (en) * 1895-08-06 William k
NZ240718A (en) 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5739273A (en) * 1992-02-12 1998-04-14 Yale University Transmembrane polypeptide and methods of use
JPH09278793A (ja) * 1996-04-10 1997-10-28 Kinichiro Miura ポリペプチド
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CN1350544A (zh) * 1999-03-11 2002-05-22 格莱风科学公司 可溶性膜蛋白受体结构域的化学合成及应用
CA2400214A1 (en) 2000-02-11 2001-11-15 Amgen Inc. Fusion receptor from tnf family
US20030143668A1 (en) * 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
EP1593060A2 (en) 2003-01-21 2005-11-09 The Trustees Of The University Of Pennsylvania Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
EP1789452B1 (en) 2004-08-25 2012-04-25 Janssen Pharmaceutica NV Relaxin-chimeric polypeptides and their preparation and use
KR20070112155A (ko) * 2005-02-08 2007-11-22 리서치 디벨럽먼트 파운데이션 가용성 Ｇ-단백질 연결 수용체(ｓＧＰＣＲ)와 관련된조성물 및 방법
BRPI0502759B1 (pt) * 2005-06-30 2014-02-25 óleo lubrificante e composição lubrificante para uma máquina de refrigeração
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
DK2121919T3 (da) 2007-03-22 2012-05-21 Heptares Therapeutics Ltd Mutante g-proteinkoblede receptorer og fremgangsmåder til udvælgelse heraf
US20100249022A1 (en) 2007-05-18 2010-09-30 University Of Massachusetts Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
US20110112037A1 (en) 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
SI2531492T1 (sl) 2010-02-05 2016-08-31 Heptares Therapeutics Limited Derivati 1,2,4-triazin-4-amina
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2012098413A1 (en) 2011-01-21 2012-07-26 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
SG10201701547VA (en) 2011-02-23 2017-03-30 Massachusetts Inst Technology Water soluble membrane proteins and methods for the preparation and use thereof
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US20130273585A1 (en) 2012-04-11 2013-10-17 Gangagen, Inc. Soluble cytoplasmic expression of heterologous proteins in escherichia coli
WO2015148820A1 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089899A2 (en) * 2006-02-01 2007-08-09 Oklahoma Medical Research Foundation Water-soluble (g protein)-coupled receptor protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Khafizov, et al., J. Mol Model 13,pp. 401-409 (2007).
Nagarajan Vaidehi 등 PNAS, 99 (20) 12622-12627(2002.10.01.)
Park, S.H., Nature, vol. 491, pp. 779-784 (Nov. 2012).

Also Published As

Publication number Publication date
CL2013002419A1 (es) 2014-06-06
AU2016201914A1 (en) 2016-04-21
MX2013009715A (es) 2014-02-28
US20140243277A1 (en) 2014-08-28
EA201391041A1 (ru) 2014-04-30
US9309302B2 (en) 2016-04-12
BR112013020969A2 (pt) 2018-07-10
EP2709647B1 (en) 2019-08-07
CA2827187A1 (en) 2012-08-30
US20180312562A1 (en) 2018-11-01
WO2012116203A1 (en) 2012-08-30
EP2709647A4 (en) 2015-01-21
MX347038B (es) 2017-04-10
SG10201701547VA (en) 2017-03-30
JP6263773B2 (ja) 2018-01-24
AU2012220558A1 (en) 2013-08-22
CN103458915A (zh) 2013-12-18
US20120252719A1 (en) 2012-10-04
CA2827187C (en) 2019-01-08
IL261151A (en) 2018-10-31
SG192646A1 (en) 2013-09-30
EP2709647A1 (en) 2014-03-26
US10035837B2 (en) 2018-07-31
CN108752461A (zh) 2018-11-06
JP2014508763A (ja) 2014-04-10
IL227886A0 (en) 2013-09-30
US8637452B2 (en) 2014-01-28
AU2017261525A1 (en) 2017-12-07
US20160264640A1 (en) 2016-09-15
KR20140027117A (ko) 2014-03-06

Similar Documents

Publication Publication Date Title
KR101963914B1 (ko) 수용성 막 단백질 및 이의 제조 방법 및 이의 사용 방법
US6548636B2 (en) Sulfated CCR5 peptides for HIV-1 infection
AU2009253623B2 (en) A soluble tumor necrosis factor receptor mutant
US20180118806A1 (en) Engineered replacement of partial variant water soluble membrane proteins
CA2456183C (en) Il-6/ds-sil-6r fusion protein
Limatola et al. Cysteine residues are critical for chemokine receptor CXCR2 functional properties
CN114258317B (zh) 用于治疗炎性病症的方法和组合物
HK1194294B (en) Water soluble membrane proteins and methods for the preparation and use thereof
HK1194294A (en) Water soluble membrane proteins and methods for the preparation and use thereof
AU2001247674A1 (en) Binding compounds and methods for identifying binding compounds
US20230265164A1 (en) QTY FC Fusion Water Soluble GPCR Proteins
JP2008501620A (ja) 細胞の生存、分化及び／又はシナプスの可塑性を調整する方法
EP3941932A1 (en) Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130917

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170221

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180516

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20181227

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190325

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190325

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220310

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220310

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240308

Start annual number: 6

End annual number: 6